Designed for Contact, Tuned for Control: A CD2-Integrated T-Cell Engager Strategy for Superior Anti-Tumor Immunity
- EvolveImmune Therapeutics is pioneering next generation multispecific CD3-T-cell engagers (TcEs) with integrated CD2 costimulation, to optimize T-cell fitness for deeper and more durable patient benefits
- The EVOLVE platform provides superior T-cell activation, proliferation and tumor cell killing compared to first generation bispecific CD3-TcEs, without excess cytokine release or tonic T-cell activation
- EVOLVE104 is a trispecific TcE that binds to the UL Binding Proteins 2/5/6 (ULBP2/5/6) on tumor cells and both CD3 and CD2 on T-cells. EVOLVE104 demonstrates a promising preclinical profile, including enhanced T-cell activation and killing of ULBP2/5/6-positive tumor cells compared to first generation bispecific CD3-TcEs. No safety concerns were identified in nonclinical toxicity studies
- EVOLVE104 is currently being evaluated in a first-in-human Phase 1a/1b trial with advanced urothelial carcinomas and squamous cell carcinomas (NCT07217171). Study objectives include assessing the safety, efficacy, pharmacokinetics and pharmacodynamics of EVOLVE104 and identifying the recommended phase 2 dose (RP2D)